Spectranetics Corp  

(Public, NASDAQ:SPNC)   Watch this stock  
Find more results for The Spectranetics Corp
34.32
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 20.07 - 35.56
Open     -
Vol / Avg. 0.00/457,720.00
Mkt cap 1.44B
P/E     -
Div/yield     -
EPS -0.61
Shares 41.92M
Beta 1.08
Inst. own 104%
Feb 25, 2015
Q4 2014 Spectranetics Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 4, 2014
Spectranetics Analyst & Investor Day - Webcast
Dec 3, 2014
Spectranetics at Piper Jaffray Healthcare Conference - Webcast
Nov 20, 2014
Spectranetics at Canaccord Genuity Medical Technologies & Diagnostics Forum - Webcast
Nov 19, 2014
Spectranetics at Stifel Healthcare Conference - Webcast
Oct 23, 2014
Q3 2014 Spectranetics Corp Earnings Call - Webcast
Oct 23, 2014
Q3 2014 Spectranetics Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -23.72% -0.23%
Operating margin -20.13% 0.25%
EBITD margin - 9.76%
Return on average assets -11.83% -0.23%
Return on average equity -31.43% -0.27%
Employees 575 -
CDP Score - -

Address

9965 Federal Drive
COLORADO SPRINGS, CO 80921
United States - Map
+1-719-6338333 (Phone)
+1-877-4472022 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. Its single-use laser catheters contain up to 250 small diameter, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of lockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries; support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); therapeutic infusion system catheters for vascular delivery of drugs and diagnostic agents, and aspiration and thrombectomy catheters for the removal of thrombus (thrombus management). In July 2014, Spectranetics Corp acquired AngioScore Inc..

Officers and directors

R. John Fletcher Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Scott William Drake President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Guy A. Childs Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shahriar Matin Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
Paul Gardon Senior Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Kimberly McIntosh Bridges Senior Vice President - Sales and Marketing of Vascular Intervention
Age: 40
Bio & Compensation  - Reuters
Donna Ford-Serbu Senior Vice President - Sales and Marketing of Lead Management
Age: 45
Bio & Compensation  - Reuters
Robert Michael Fuchs Senior Vice President, Global Head - Human Resources
Age: 47
Bio & Compensation  - Reuters
Austin B. Byrd Chief Compliance Officer, Vice President
Age: 48
Bio & Compensation  - Reuters
Wade A. Bowe Vice President - Research & Development
Age: 43
Bio & Compensation  - Reuters